2D cell cultures lack the ability to replicate the complex tissue organization found in the human body. Despite using human cells, traditional cell cultures fall short due to the absence of hierarchical structure, cellular diversity, and interactions between cells and their environment. This limitation prevents cell lines from accurately mimicking the functions present in real tissues, making the results from 2D cultures less predictive of clinical outcomes.

Organoid culture is a complex and time-consuming process, with many protocols involving numerous manual steps that increase the risk of failure. Regulatory bodies demand robust and reproducible data from preclinical experiments to approve first-in-human trials. Relying on traditional cultivation methods is likely to continue resulting in setbacks and inefficiencies.

While liquid-handling robots can automate manual steps, their use in 3D cell culture results in high consumable costs and significant variability in organoid production. Organ-on-a-Chip (OoC) technology increases in vitro model complexity but suffers from low experimental throughput and is typically restricted to modeling a single organ. In silico methods offer the fastest and most cost-effective predictions, but they are limited in effectiveness when not combined with other New Approach Methodologies (NAMs).

Human organoid cultures overcome the limitations of traditional 2D cell cultures by accurately replicating the complex architecture and cellular interactions found in real tissues. Unlike flat, two-dimensional models, organoids provide a dynamic environment where cells can organize, differentiate, and interact in ways that closely mirror actual human organs. This enables organoid-based studies to yield data that is far more predictive of how treatments will perform in clinical settings.

Our NanoLab System™ (NLS™) is expertly crafted to provide a comprehensive, plug-and-play organ-on-chip (OoC) platform. It adeptly manages the full spectrum of processes, from the initial differentiation of induced pluripotent stem cells (iPSC) to the intricate culture and ongoing maintenance of organoids. Designed for robust compatibility, NLS™ effortlessly integrates with standard imaging systems, enhancing both functionality and efficiency in laboratory settings.

By integrating automated organ-on-chip (OoC) technology with advanced computer vision, we aim to dramatically enhance the predictive accuracy of drug and chemical safety screenings. Our goal is to broaden the use of organoids and propel the pharmaceutical and biotechnology industries into a new era of patient-centric preclinical experiments. This approach not only improves outcomes but also aligns with the evolving demands of healthcare research.